Terms ending in 2036
Every in-force patent on BioAtla Inc.'s record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,513,699 | Discovering and Producing Conditionally Active Biologic Proteins in the Same Eukaryotic Cell Production Hosts In force · High confidence | BioAtla, Inc. | In force | High confidence | |
| US 11,254,932 | Conditionally Active Biological Proteins In force · High confidence | BioAtla, Inc. | In force | High confidence | |
| US 12,110,611 | Conditionally Active Biological Proteins In force · Low confidence | BioAtla, Inc. | In force | Low confidence | |
| US 11,827,704 | Antibody Molecules to PD-1 and Uses Thereof In force · High confidence | Novartis AG | In force | High confidence | |
| US 10,563,194 | Conditionally Active Biological Proteins In force · High confidence | BioAtla, Inc. | In force | High confidence | |
| US 11,111,288 | Conditionally Active Chimeric Antigen Receptors for Modified T-Cells In force · High confidence | BioAtla, Inc. | In force | High confidence | |
| US 12,187,801 | Chimeric Antigen Receptors Against Axl or ROR2 and Methods of Use Thereof In force · Medium confidence | Inc., BioAtla | In force | Medium confidence | |
| US 10,851,165 | Antibody Molecules to PD-L1 and Methods of Treating Cancer In force · Medium confidence | Novartis AG | In force | Medium confidence | |
| US 12,631,650 | Proteins Targeting Orthologs In force · High confidence | BioAtla, Inc. | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
6 of these are in force and held by BioAtla Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.